Dean Fanelli, Ph.D.


Seyfarth Shaw LLP

Dean L. Fanelli, Ph.D. is a partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington D.C. office. Dr. Fanelli’s practice focuses on the chemical, pharmaceutical, and biotechnology industries and his expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions, and inter partes review and post grant review proceedings. Dr. Fanelli also focuses his practice on Paragraph IV litigation strategies, Hatch-Waxman litigation, and biosimilar market assessment and litigation strategy.

Dr. Fanelli’s focus is on pharmaceutical and chemical related technologies including those in the fields of new chemical entities, pharmaceutical formulations, polymers, diagnostics, and medical devices. He also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, and financing for life sciences companies as well as Paragraph IV ANDA analyses and associated Hatch-Waxman Paragraph IV litigation.

Dr. Fanelli actively participates in the American Intellectual Property Law Association (AIPLA), American Bar Association and American Chemical Society. He is also a member of AIPLA‘s Intellectual Property Practice in Japan Committee. Dr. Fanelli’s articles have been published in peer-reviewed scientific journals, and he has given presentations and published articles on various topics related to intellectual property.

Dr. Fanelli graduated from The George Washington University Law School and received his Ph.D. in Organic Chemistry from Temple University, after receiving his B.S. in Chemistry from Villanova University